Literature DB >> 7277206

Evidence of nonlinearity in digoxin pharmacokinetics.

J G Wagner, K D Popat, S K Das, E Sakmar, H Movahhed.   

Abstract

Six normal male volunteers received 0.5 mg label doses of digoxin as (a) a bolus intravenous injection over 2 min, (b) a constant rate intravenous infusion over 1 hr, (c) a constant rate intravenous infusion over 3 h, and (d) a solution in 5% dextrose given orally. Plasma concentrations of digoxin were measured by radioimmunoassay for a 4 day period and urinary excretion for a 6 day period after the single doses. The mean (coefficient of variation) total areas under the plasma concentration-time curves per 0.5 mg of digoxin were (a) 35.55 (14.8%), (b) 30.20 (27.7%), (c) 25.80 (35.5%), and (d) 15.47 (49.9%); the means differed significantly (0.01 greater than p greater than 0.005). The mean (coefficient of variation) total amounts excreted in the urine as a fraction of the dose were (a) 0.689 (6.31%), (b) 0.517 (20.4%), (c) 0.588 (16.8%), and (d) 0.374 (23.4%); the means differed significantly (p less than 0.001). Both the total clearance and the nonrenal clearance of digoxin differed significantly with the method of intravenous administration. The slower the rate of input of digoxin to the body, the greater were both the total clearance and the nonrenal clearance of the drug, which strongly suggests nonlinear pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7277206     DOI: 10.1007/BF01068079

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  20 in total

1.  Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses.

Authors:  J R Koup; D J Greenblatt; W J Jusko; T W Smith; J Koch-Weser
Journal:  J Pharmacokinet Biopharm       Date:  1975-06

2.  The effect of the upright posture upon hepatic blood flow in normotensive and hypertensive subjects.

Authors:  J W CULBERTSON; R W WILKINS; F J INGELFINGER; S E BRADLEY
Journal:  J Clin Invest       Date:  1951-03       Impact factor: 14.808

3.  Comparison of the in vitro and in vivo release of digoxin from four different soft gelatin capsule formulations.

Authors:  J G Wagner; R G Stoll; D J Weidler; J W Ayres; M R Hallmark; E Sakmar; A Yacobi
Journal:  J Pharmacokinet Biopharm       Date:  1979-04

4.  Absorption of digoxin from different oral preparations in normal subjects during steady state.

Authors:  D H Huffman; C V Manion; D L Azarnoff
Journal:  Clin Pharmacol Ther       Date:  1974-08       Impact factor: 6.875

5.  Absorption of orally given digoxin preparations.

Authors:  D H Huffman; D L Azarnoff
Journal:  JAMA       Date:  1972-11-20       Impact factor: 56.272

6.  Pharmacokinetics and bioavailability of digoxin capsules, solution and tablets after single and multiple doses.

Authors:  B L Lloyd; D J Greenblatt; M D Allen; J S Harmatz; T W Smith
Journal:  Am J Cardiol       Date:  1978-07       Impact factor: 2.778

7.  Absorption of digoxin in man after oral and intrasigmoid administration studied by portal vein catheterization.

Authors:  K E Andersson; L Nyberg; H Dencker; J Göthlin
Journal:  Eur J Clin Pharmacol       Date:  1975-10-10       Impact factor: 2.953

8.  Digoxin bioavailability: formulations and rates of infusions.

Authors:  F I Marcus; J Dickerson; S Pippin; M Stafford; R Bressler
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

9.  The question of cumulation of digoxin metabolites in renal failure.

Authors:  T P Gibson; H A Nelson
Journal:  Clin Pharmacol Ther       Date:  1980-02       Impact factor: 6.875

10.  Biotransformation and elimination of digoxin with normal and minimal renal function.

Authors:  M H Gault; D Sugden; C Maloney; M Ahmed; M Tweeddale
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

View more
  3 in total

1.  Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.

Authors:  Daniel Moj; Nina Hanke; Hannah Britz; Sebastian Frechen; Tobias Kanacher; Thomas Wendl; Walter Emil Haefeli; Thorsten Lehr
Journal:  AAPS J       Date:  2016-11-07       Impact factor: 4.009

2.  On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin.

Authors:  K O Haustein; R G Alken; H J Lach; U Becker; N Rietbrock
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations.

Authors:  K O Haustein
Journal:  J Pharmacokinet Biopharm       Date:  1986-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.